Time-Out Procedures e592 4.2. Ethical Aspects e592 4.2.1. Informed Consent e592 4.2.2. Potential Conflicts of Interest e592 4.3. Radiation Safety: Recommendation e592 4.4. Contrast-Induced AKI: Recommendations e593 4.5. Anaphylactoid Reactions: Recommendations e594 4.6. Statin Treatment: Recommendation e594 4.7. Bleeding Risk: Recommendation e594 4.8. PCI in Hospitals Without On-Site Surgical Backup: Recommendations e594 5. Procedural Considerations e595 5.1. Vascular Access: Recommendation e595 5.2. PCI in Specific Clinical Situations e596 5.2.1. UA/NSTEMI: Recommendations e596 5.2.2. ST-Elevation Myocardial Infarction e597 5.2.2.1. Coronary Angiography Strategies in STEMI: Recommendations e597 5.2.2.2. Primary PCI of the Infarct Artery: Recommendations e598 5.2.2.3. Delayed or Elective PCI in Patients With STEMI: Recommendations e599 5.2.3. Cardiogenic Shock: Recommendations e600 5.2.3.1. Procedural Considerations for Cardiogenic Shock e600 5.2.4. Revascularization Before Noncardiac Surgery: Recommendations e600 5.3. Coronary Stents: Recommendations e601 5.4. Adjunctive Diagnostic Devices e602 5.4.1. FFR: Recommendation e602 5.4.2. IVUS: Recommendations e602 5.4.3. Optical Coherence Tomography e603 5.5. Adjunctive Therapeutic Devices e603 5.5.1. Coronary Atherectomy: Recommendations e603 5.5.2. Thrombectomy: Recommendation e603 5.5.3. Laser Angioplasty: Recommendations e603 5.5.4. Cutting Balloon Angioplasty: Recommendations e603 5.5.5. Embolic Protection Devices: Recommendation e604 5.6. Percutaneous Hemodynamic Support Devices: Recommendation e604 5.7. Interventional Pharmacotherapy e604 5.7.1. Procedural Sedation e604 5.7.2. Oral Antiplatelet Therapy: Recommendations e605 Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e575 5.7.3. IV Antiplatelet Therapy: Recommendations e606 5.7.4. Anticoagulant Therapy e607 5.7.4.1. Use of Parenteral Anticoagulants During PCI: Recommendation e607 5.7.4.2. UFH: Recommendation e607 Recommendations e608 5.7.4.4. Bivalirudin and Argatroban: Recommendations e608 Recommendation e609 5.7.5. No-Reflow Pharmacological Therapies: Recommendation e610 5.8. PCI in Specific Anatomic Situations e610 5.8.1. CTOs: Recommendation e610 5.8.2. SVGs: Recommendations e610 5.8.3. Bifurcation Lesions: Recommendations e611 5.8.4. Aorto-Ostial Stenoses: Recommendations e611 5.8.5. Calcified Lesions: Recommendation e611 5.9. PCI in Specific Patient Populations e612 5.9.1. Elderly e612 5.9.2. Diabetes e612 5.9.3. Women e612 5.9.4. CKD: Recommendation e612 5.9.5. 